Promise and Challenges of T Cell Immunotherapy for Osteosarcoma

por Park, Jeong A, Cheung, Nai-Kong V.
Publicado 2023

Targets and Antibody Formats for Immunotherapy of Neuroblastoma

por Park, Jeong A., Cheung, Nai-Kong V.
Publicado 2020

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

por Park, Jeong A., Cheung, Nai-Kong V.
Publicado 2020

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor

por Espinosa-Cotton, Madelyn, Cheung, Nai-Kong V.
Publicado 2021

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies

por Park, Jeong A, Cheung, Nai-Kong V
Publicado 2022

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2

por Ahmed, Mahiuddin, Hu, Jian, Cheung, Nai-Kong V.
Publicado 2014

Immunotherapy of Childhood Sarcomas

por Roberts, Stephen S., Chou, Alexander J., Cheung, Nai-Kong V.
Publicado 2015

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy

por Santich, Brian H., Cheung, Nai-Kong V., Klein, Christian
Publicado 2020

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response

por Park, Jeong A., Wang, Linlin, Cheung, Nai-Kong V.
Publicado 2021

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

por Casey, Dana L., Lin, Tsung-Yi, Cheung, Nai-Kong V.
Publicado 2019

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells

por Yu, Eun Young, Cheung, Nai-Kong V., Lue, Neal F.
Publicado 2022

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody

por Ahmed, Mahiuddin, Cheng, Ming, Cheung, Irene Y, Cheung, Nai-Kong V
Publicado 2015

A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy

por Xu, Hong, Buhtoiarov, Ilia N., Guo, Hongfen, Cheung, Nai-Kong V.
Publicado 2021

Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors

por Espinosa-Cotton, Madelyn, Guo, Hong-Fen, Tickoo, Satish K., Cheung, Nai-Kong V.
Publicado 2023

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

por Ahmed, Mahiuddin, Goldgur, Yehuda, Hu, Jian, Guo, Hong-Fen, Cheung, Nai-Kong V.
Publicado 2013

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies

por Hoseini, Sayed Shahabuddin, Espinosa-Cotton, Madelyn, Guo, Hong-fen, Cheung, Nai-Kong V
Publicado 2020

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

por Cheung, Nai-Kong V., Guo, Hongfen, Hu, Jian, Tassev, Dimiter V., Cheung, Irene Y.
Publicado 2012

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

por Hoseini, Sayed Shahabuddin, Dobrenkov, Konstantin, Pankov, Dmitry, Xu, Xiaoliang L., Cheung, Nai-Kong V.
Publicado 2017

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

por Park, Jeong A, Espinosa-Cotton, Madelyn, Guo, Hong-fen, Monette, Sebastien, Cheung, Nai-Kong V
Publicado 2023

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

por Cheng, Ming, Santich, Brian H., Xu, Hong, Ahmed, Mahiuddin, Huse, Morgan, Cheung, Nai-Kong V.
Publicado 2016